Payment & Shipping Terms:
|Usage:||Ranolazine Hydrochloride Intermediate||CAS:||2210-74-4|
|Name:||1 - ( 2 - Methoxyphenoxy ) Methyl Oxidant|
95635 55 5,
5294 61 1
CAS : 2210-74-4 Ranolazine Intermediate 1 - ( 2 - Methoxyphenoxy ) methyl oxirane
Chemical Name : 1 - ( 2 - Methoxyphenoxy ) methyl oxirane
CAS No . : 2210-74-4
Synonyms : Glycidyl 2 - Methoxyphenyl ethe r; 1 - ( Glycidyloxy ) - 2- methoxybenzene
Molecular Formula : C10H12O3
Molecular Weight : 180.2
Appearance : Off white solid
Melting Point : 33 - 36 Deg C
Usage : Ranolazine Intermediate
Ranolazine is the active pharmaceuical Ingredient ( API ) of Ranexa which is used to treat chronic chest pain. It may be used concomitantly with other drugs such as ACE inhibitors , andangiotensin receptor blockers , antiplatelet therapy , β blockers , calcium channel blockers , lipid-lowering therapy and nitrates.
It was first arrpoved by FDA in 2006 and marketed by Gilead. It was also approved by Europe EMEA in 2008.
Syntex Inc. originally began the ranolazine development in 1985 and completed 61 studies till1994. Afterwards, Phase II studies were done but it was found that the formulation did not result in adequate plasma concentrations of drug. Then the sustained-release ( SR ) formulation was created.
In 1996, CV Therapeutics got the North American and European rights to ranolazine from Syntex accquired by Roche in 1994 and then in 2006, accquired the remaining worldwide rights to ranolazine. In 2008 Menarini accquired exclusively rights for ranolazine in Europe and some other countries from CV and then Gilead accuired CV in 2009. Gilead expanded the partnership with Menarini to include additional countries in 2013.
1 - ( 2 - Methoxyphenoxy ) methyl oxirane CAS No. : 2210-74-4 is one of its intermediates. There are several synthesis routes to manufacture this intermediate but some routes are protected by the patents in some countries including Europe, USA and China. We strictly obey the laws and our commercial products are manufactured without infringing such patents. But anyway, the buyers should know the patent status by themselves. We promise to supply the real route of synthesis to the buyers. The buyers should take the risks of patent infringement by themselves.
Competitive Advantage: Produced under cGMP conditions, support customers’ registrations.